Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2023

01-12-2023 | Thrombotic Microangiopathy | Case report

Bleomycin/cisplatin/etoposide

Renal-limited thrombotic microangiopathy

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Rizvi A, et al. Renal-Limited Thrombotic Microangiopathy from Bleomycin-Etoposide- Cisplatin Chemotherapy in a Young Male with Testicular Cancer. Journal of the American Society of Nephrology 34: 783, Jan 2023 [abstract]
Metadata
Title
Bleomycin/cisplatin/etoposide
Renal-limited thrombotic microangiopathy
Publication date
01-12-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-50890-6

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Hydralazine

Case report

Metformin

Case report

Pembrolizumab

Case report

Rituximab

Case report

Ipilimumab/nivolumab

Case report

Multivitamin